{"title":"雷喹莫德治疗实验感染小鼠慢性弓形虫病的疗效","authors":"R. Brakat, N. Badr, S. Soliman, S. Sharaf-El-Deen","doi":"10.21608/jesp.2023.331739","DOIUrl":null,"url":null,"abstract":"Toxoplasmosis is a zoonotic protozoan infectious disease affects people worldwide with a high rate of morbidity and mortality. The incomplete efficacy of the approved drugs for the chronic Toxoplasma gondii infections endangers one-third of the global humans and animals with reactivation. This is due to the risky complications chronic toxoplasmosis causes. This study evaluated the TLRs 7/8 agonist, Resiquimod ® for treating chronic toxoplasmosis in BALB/c mice infected with the ME49 strain of T. gondii as compared the traditionally used Py-rimethamine ® & Sulphadiazine ® . This was judged by the number of brain cysts, the histpatholo-gical degrees in the brain and retina, expression of the apoptotic marker, caspase-3 compared to negative and positive controls. The results showed a statistically significant decrease in the number of brain cysts in resiq-uimod-treated mice correlated with the histopathological improvement of brain and retina and apoptosis.","PeriodicalId":17289,"journal":{"name":"Journal of the Egyptian Society of Parasitology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE\",\"authors\":\"R. Brakat, N. Badr, S. Soliman, S. Sharaf-El-Deen\",\"doi\":\"10.21608/jesp.2023.331739\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Toxoplasmosis is a zoonotic protozoan infectious disease affects people worldwide with a high rate of morbidity and mortality. The incomplete efficacy of the approved drugs for the chronic Toxoplasma gondii infections endangers one-third of the global humans and animals with reactivation. This is due to the risky complications chronic toxoplasmosis causes. This study evaluated the TLRs 7/8 agonist, Resiquimod ® for treating chronic toxoplasmosis in BALB/c mice infected with the ME49 strain of T. gondii as compared the traditionally used Py-rimethamine ® & Sulphadiazine ® . This was judged by the number of brain cysts, the histpatholo-gical degrees in the brain and retina, expression of the apoptotic marker, caspase-3 compared to negative and positive controls. The results showed a statistically significant decrease in the number of brain cysts in resiq-uimod-treated mice correlated with the histopathological improvement of brain and retina and apoptosis.\",\"PeriodicalId\":17289,\"journal\":{\"name\":\"Journal of the Egyptian Society of Parasitology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Egyptian Society of Parasitology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/jesp.2023.331739\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian Society of Parasitology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/jesp.2023.331739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE
Toxoplasmosis is a zoonotic protozoan infectious disease affects people worldwide with a high rate of morbidity and mortality. The incomplete efficacy of the approved drugs for the chronic Toxoplasma gondii infections endangers one-third of the global humans and animals with reactivation. This is due to the risky complications chronic toxoplasmosis causes. This study evaluated the TLRs 7/8 agonist, Resiquimod ® for treating chronic toxoplasmosis in BALB/c mice infected with the ME49 strain of T. gondii as compared the traditionally used Py-rimethamine ® & Sulphadiazine ® . This was judged by the number of brain cysts, the histpatholo-gical degrees in the brain and retina, expression of the apoptotic marker, caspase-3 compared to negative and positive controls. The results showed a statistically significant decrease in the number of brain cysts in resiq-uimod-treated mice correlated with the histopathological improvement of brain and retina and apoptosis.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
